

HR 7296

MMAPPP Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 22, 2020

Current Status: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary

Latest Action: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (Jun 22, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/7296>

Sponsor

Name: Rep. Schakowsky, Janice D. [D-IL-9]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors (34 total)

Cosponsor	Party / State	Role	Date Joined
Rep. DeFazio, Peter A. [D-OR-4]	D · OR		Jun 22, 2020
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Jun 22, 2020
Rep. Doggett, Lloyd [D-TX-35]	D · TX		Jun 22, 2020
Rep. Jayapal, Pramila [D-WA-7]	D · WA		Jun 22, 2020
Rep. Pocan, Mark [D-WI-2]	D · WI		Jun 22, 2020
Rep. Rooney, Francis [R-FL-19]	R · FL		Jun 22, 2020
Rep. Velazquez, Nydia M. [D-NY-7]	D · NY		Jun 24, 2020
Rep. Bishop, Sanford D., Jr. [D-GA-2]	D · GA		Jun 26, 2020
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Jul 6, 2020
Rep. Carson, Andre [D-IN-7]	D · IN		Jul 6, 2020
Rep. Cohen, Steve [D-TN-9]	D · TN		Jul 6, 2020
Rep. Hayes, Jahana [D-CT-5]	D · CT		Jul 6, 2020
Rep. Huffman, Jared [D-CA-2]	D · CA		Jul 6, 2020
Rep. McCollum, Betty [D-MN-4]	D · MN		Jul 6, 2020
Rep. Pingree, Chellie [D-ME-1]	D · ME		Jul 6, 2020
Rep. Porter, Katie [D-CA-45]	D · CA		Jul 6, 2020
Rep. Raskin, Jamie [D-MD-8]	D · MD		Jul 6, 2020
Rep. Scanlon, Mary Gay [D-PA-5]	D · PA		Jul 6, 2020
Rep. Welch, Peter [D-VT-At Large]	D · VT		Jul 6, 2020
Del. San Nicolas, Michael F. Q. [D-GU-At Large]	D · GU		Jul 20, 2020
Rep. Khanna, Ro [D-CA-17]	D · CA		Jul 20, 2020
Rep. Napolitano, Grace F. [D-CA-32]	D · CA		Jul 20, 2020
Rep. Chu, Judy [D-CA-27]	D · CA		Aug 7, 2020
Rep. Gabbard, Tulsi [D-HI-2]	D · HI		Aug 7, 2020
Rep. Hastings, Alcee L. [D-FL-20]	D · FL		Aug 7, 2020
Rep. Luria, Elaine G. [D-VA-2]	D · VA		Aug 7, 2020
Rep. DeSaulnier, Mark [D-CA-11]	D · CA		Aug 18, 2020
Rep. Lawson, Al, Jr. [D-FL-5]	D · FL		Aug 18, 2020
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Sep 25, 2020
Rep. Rose, Max [D-NY-11]	D · NY		Sep 25, 2020
Rep. Evans, Dwight [D-PA-3]	D · PA		Oct 23, 2020
Rep. Price, David E. [D-NC-4]	D · NC		Oct 30, 2020
Rep. Titus, Dina [D-NV-1]	D · NV		Oct 30, 2020
Rep. Phillips, Dean [D-MN-3]	D · MN		Dec 2, 2020

Committee Activity

Committee	Chamber	Activity	Date
Armed Services Committee	House	Referred To	Jun 22, 2020
Energy and Commerce Committee	House	Referred To	Jun 22, 2020
Judiciary Committee	House	Referred To	Jun 22, 2020
Science, Space, and Technology Committee	House	Referred To	Jun 22, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 4439	Related bill	Aug 5, 2020: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Jun 22, 2020)

Make Medications Affordable by Preventing Pandemic Price gouging Act of 2020 or the MMAPPP Act of 2020

This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies.

With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill.

The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access.

If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.

Actions Timeline

- **Jun 22, 2020:** Introduced in House
- **Jun 22, 2020:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.